CompanyGraph
Pharma Research Products Co., Ltd
214450 · KRX · South Korea
pharmaresearch.co.krFinancials as of FY2025
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.46B, above the global median of $1.18B
- PositionReturn on equity is 27.3%, higher than 95% of its Biotechnology peers (median -22.3%)
- Interpretations17 currently firing — 17
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.13%Above 5Y avg (0.68%)
Annual Rate
KRW 3700.00Paid annual
Payout Ratio
22.1%Sustainable
Payback Period
82.7 yr
Last Ex-Dividend
Dec 29, 2025
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.40TKRW2.46B · vs all stocks (USD)
Trailing P/E
20.61xvs Biotechnology peers
Revenue (TTM)
603.58BKRW435.66M · vs all stocks (USD)
Profit Margin
30.76%vs Biotechnology peers
Beta
0.4800xvs all stocks
52-Week Change
-46.22%vs all stocks
Market Capitalization
3.40TKRW2.46B · vs all stocks (USD)
Enterprise Value
3.08TKRW2.23B · vs all stocks (USD)
Trailing P/E
20.61xvs Biotechnology peers
Forward P/E
13.81xvs Biotechnology peers
PEG Ratio
1.07xvs Biotechnology peers
Price to Sales (TTM)
5.64xvs Biotechnology peers
Price to Book (MRQ)
4.31xvs Biotechnology peers
Enterprise to Revenue
5.11xvs Biotechnology peers
Enterprise to EBITDA
12.21xvs Biotechnology peers
Gross Margin
76.97%vs Biotechnology peers
Profit Margin
30.76%vs Biotechnology peers
Operating Margin
37.23%vs Biotechnology peers
Return on Assets (TTM)
14.52%vs Biotechnology peers
Return on Equity (TTM)
27.34%vs Biotechnology peers
Revenue (TTM)
603.58BKRW435.66M · vs all stocks (USD)
Revenue per Share (TTM)
58.09KKRWUpdated Sep 20, 2026Quarterly Revenue Growth
27.10%vs Biotechnology peers
Gross Profit (TTM)
469.05BKRW338.56M · vs all stocks (USD)
EBITDA (TTM)
269.73BKRW194.69M · vs all stocks (USD)
Net Income (TTM)
185.69BKRW134.03M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
19.30%vs Biotechnology peers
Operating Cash Flow (TTM)
172.89BKRW124.79M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
88.13BKRW63.61M · vs all stocks (USD)
Trailing Annual Dividend Rate
3.70KKRWUpdated Sep 20, 2026Trailing Annual Dividend Yield
1.13%vs all stocks
5-Year Average Dividend Yield
0.68%vs all stocks
Payout Ratio
22.14%vs Biotechnology peers
Minority Interest (Equity)
34.55BKRWFY2025 · Dec 31, 2025Revenue
536.29BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
125.07BKRWFY2025 · Dec 31, 2025Gross Profit
411.22BKRWFY2025 · Dec 31, 2025Operating Income
214.40BKRW154.75M · vs all stocks (USD)
Pre-tax Income
216.51BKRWFY2025 · Dec 31, 2025Income Tax Expense
48.26BKRWFY2025 · Dec 31, 2025Net Income
168.26BKRWFY2025 · Dec 31, 2025EBIT
226.91BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
243.28BKRWFY2025 · Dec 31, 2025Research & Development
35.86BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
103.55BKRWFY2025 · Dec 31, 2025Other Operating Expenses
1.15BKRWFY2025 · Dec 31, 2025Non-operating Interest Income
16.23BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
10.39BKRWFY2025 · Dec 31, 2025EPS (Basic)
15.89KKRWFY2025 · Dec 31, 2025EPS (Diluted)
14.93KKRWFY2025 · Dec 31, 2025Basic Shares Outstanding
10.39MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
10.39MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
168.26BKRWFY2025 · Dec 31, 2025Minority Interests (P&L)
-3.13BKRWFY2025 · Dec 31, 2025Operating Cash Flow
128.05BKRWFY2025 · Dec 31, 2025Free Cash Flow
98.50BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
175.66BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
168.26BKRWFY2025 · Dec 31, 2025Stock-based Compensation
149.42MKRWFY2025 · Dec 31, 2025Other Non-cash Items
-5.45BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-9.46BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-25.44BKRWFY2025 · Dec 31, 2025Capital Expenditures
-29.55BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-4.88BKRWFY2025 · Dec 31, 2025Net Acquisitions
13.55BKRWFY2025 · Dec 31, 2025Purchase of Investments
-633.35BKRWFY2025 · Dec 31, 2025Sale of Investments
494.71BKRWFY2025 · Dec 31, 2025Other Investing Activity
-82.43MKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-154.71BKRWFY2025 · Dec 31, 2025Long-term Debt Payments
-981.11MKRWFY2025 · Dec 31, 2025Common Dividends Paid
-11.73BKRWFY2025 · Dec 31, 2025Other Financing Charges
-174.00MKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
-12.88BKRWFY2025 · Dec 31, 2025Shares Outstanding
10.39MSharesUpdated Sep 20, 2026Float Shares
5.57MSharesUpdated Sep 20, 2026% Held by Insiders
34.96%vs all stocks
% Held by Institutions
16.78%vs all stocks
Total Cash (MRQ)
595.64BKRW429.93M · vs all stocks (USD)
Total Cash per Share (MRQ)
57.33KKRWUpdated Sep 20, 2026Total Debt (MRQ)
220.28BKRW159.00M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2790xvs Biotechnology peers
Current Ratio (MRQ)
7.78xvs Biotechnology peers
Book Value per Share (MRQ)
75.93KKRWUpdated Sep 20, 2026Total Assets
1.04TKRW753.48M · vs all stocks (USD)
Total Current Assets
759.54BKRWFY2025 · Dec 31, 2025Total Liabilities
320.01BKRWFY2025 · Dec 31, 2025Total Non-current Assets
284.35BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
209.54BKRWFY2025 · Dec 31, 2025Total Current Liabilities
110.47BKRWFY2025 · Dec 31, 2025Cash
98.18BKRWFY2025 · Dec 31, 2025Cash Equivalents
77.48BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
175.66BKRWFY2025 · Dec 31, 2025Other Short-term Investments
438.71BKRWFY2025 · Dec 31, 2025Accounts Receivable
44.49BKRWFY2025 · Dec 31, 2025Inventory
82.70BKRWFY2025 · Dec 31, 2025Accounts Payable
11.48BKRWFY2025 · Dec 31, 2025Short-term Debt
9.64BKRWFY2025 · Dec 31, 2025Other Current Liabilities
1.78BKRWFY2025 · Dec 31, 2025Long-term Debt
859.86MKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
90.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
5.25BKRWFY2025 · Dec 31, 2025Retained Earnings
492.07BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
723.88BKRW522.49M · vs all stocks (USD)
52-Week Low
255.00KKRWUpdated Sep 20, 202652-Week High
613.00KKRWUpdated Sep 20, 202652-Week Change
-46.22%vs all stocks
Beta
0.4800xvs all stocks
50-Day MA
373.52KKRWUpdated Sep 20, 2026200-Day MA
355.54KKRWUpdated Sep 20, 2026Avg 10-Day Volume
114.48KSharesUpdated Sep 20, 2026Avg 30-Day Volume
153.07KSharesUpdated Sep 20, 2026Diluted EPS (TTM)
14.93KKRWUpdated Sep 20, 202617 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Three Asset-Base Ratios Elevated
It gets more sales from its assets than its industry does, and a lot of profit from them too.
Reads
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Earnings, Profit, and Cash Flow All Compounding
Its profit, gross profit and free cash flow have all grown across four years.
Reads
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
Revenue Growth With Elevated Margin
Revenue up in each of five years, while its operating margin stays high.
Reads
Cash Flow, Profit, and Revenue All Growing
Free cash flow and gross profit have both grown over four years, with revenue up in each of the last three.
Reads
How is this stock valued?
Down-Close Streak With Profitability
A run of down weeks on a company profitable three years running and funded by equity.
Reads
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is 27.3%, higher than 95% of its Biotechnology peers (median -22.3%)Significant
Return on equity: 0.27Industry median: -0.22Industry P95: 0.23Peers compared: 260
Financial Health
Altman Z-Score 9.02: safe zoneNotable
Altman Z-Score: 9.02
High earnings qualityNotable
Earnings Quality Score: 0.52
High structural barrier to entryNotable
Barrier to Entry: 0.58
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.46B, above the global median of $1.18BNotable
Market cap (USD): 2,456,003,695.896Global Median: 1,180,223,658.953
Levered free cash flow is $63.61M, above the global median of $18.73MNotable
Levered free cash flow (USD): 63,611,709.869Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
HUTCHMED
Tier 1ProductionApproval-Gated PipelineRule
Double Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Celldex Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Immunome Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Supernus Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
GN Store Nord A/S
Tier 1ProductionApproval-Gated PipelineRuleFlow
China Resources Double Crane Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Butterfly Network Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Disc Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beam Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
NVIDIA Corporation
16 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsCash Flow, Profit, and Revenue All GrowingEarnings, Profit, and Cash Flow All CompoundingThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And Margin
Suzhou TFC Optical Communication Co., Ltd.
14 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsCash Flow, Profit, and Revenue All GrowingEarnings, Profit, and Cash Flow All CompoundingMulti-Year FCF With Growth And Margin
Catalyst Pharmaceuticals Inc.
13 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And Margin